Compare MYSZ & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | PRPO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | MYSZ | PRPO |
|---|---|---|
| Price | $0.79 | $23.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 92.8K | 7.7K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,512,000.00 | ★ $22,800,000.00 |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $0.73 | $3.90 |
| 52 Week High | $5.00 | $28.50 |
| Indicator | MYSZ | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 48.54 |
| Support Level | $0.75 | $22.40 |
| Resistance Level | $0.86 | $24.60 |
| Average True Range (ATR) | 0.04 | 1.32 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 14.34 | 35.84 |
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.